Application of Ulex europaeus agglutinin 1-modified liposomes for oral vaccine: ex vivo bioadhesion and in vivo immunity

DOI Web Site Web Site 参考文献17件
  • Li KeXin
    School of Pharmacy, Shenyang Pharmaceutical University Vocational and Technical School, Shenyang Pharmaceutical University
  • Zhao XiuLi
    School of Pharmacy, Shenyang Pharmaceutical University
  • Xu ShiYi
    Vocational and Technical School, Shenyang Pharmaceutical University
  • Pang DaHai
    Shenyang Food and Drug Administration
  • Yang ChunRong
    School of Pharmacy, Shenyang Pharmaceutical University
  • Chen DaWei
    School of Pharmacy, Shenyang Pharmaceutical University

書誌事項

タイトル別名
  • Application of Ulex europaeus Agglutinin I-Modified Liposomes for Oral Vaccine: Ex Vivo Bioadhesion and in Vivo Immunity

この論文をさがす

抄録

The conjugation of Ulex europaeus agglutinin I (UEAI) onto surface of liposomes has been demonstrated to effectively improve the intestinal absorption of antigen, subsequently induced strong mucosal and systemic immune responses. In this context, we prepared bovine serum albumin (BSA)-encapsulating UEAI-modified liposomes (UEAI-LIP) and unmodified ones (LIP). The specific bioadhesion on mice gastro-intestinal mucosa was studied ex vivo. An important increase of interaction between UEAI-conjugated liposomes and the intestinal segments with Peyer's Patches (PPs) was observed compared with the unconjugated one (p<0.01). However, under the presence of α-L-fucose, which is the reported specific sugar for UEAI, specifically inhibited the activity of these conjugates. The immune-stimulating activity in vivo was studied by measuring immunoglobulin G (IgG) levels in serum and immunoglobulin A (IgA) levels in intestinal mucosal secretions following oral administration of BSA solution, LIP and UEAI-LIP in mice. Results indicate that antigen encapsulated in liposomes, especially the UEAI-modified ones, was favorable for inducing immune response. At 42 d after the first immunization, the highest IgG and IgA antibody levels produced by UEAI-LIP occurred, respectively showing 4.4-fold and 5-fold higher levels compared to those of the groups receiving BSA alone. This data demonstrated high potential of UEAI-modified liposomes for their use as carrier for oral vaccines.

収録刊行物

参考文献 (17)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ